S - 1 单药或联合方案治疗转移性肺癌的疗效和安全性简

目的：探讨S-1单药或联合方案治疗转移性肺癌的疗效和安全性。方法：36例转移性肺癌患者接受如下方案治疗：S～1单药组：S-1用量为40mg／m^2，口服，bid，第1—14天，21天为一个周期。S-1联合多西他赛组（TS方案）：S-1用量为40mg／m^2，口服，bid，第1—14天，多西他赛75mg／m^2，静脉滴注，第1天；21天为一个周期。结果：S-1单药组患者的ORR为14．3％，CBR为35．7％，而S-1联合多西他赛组ORR为22．7％，CBR为72．7％，两组ORR差异无统计学意义（P〉0．05），CBR差异有统计学意义（P〈0．05）。结论：S一1单药或者含S～1联合方案是转移性肺癌治疗的有效选择方案，患者不良反应可耐受。

Efficacy and safety of regimens of S -1 based chemotherapy in the treatment of metastatic lung cancer

Objective： To evaluate the efficacy and toxicity of S - 1 based chemotherapy in the treatment of meta- static lung cancer. Methods：Thirty - six patients with metastatic lung cancer were treated with S - 1 based chemo- therapy regimens. They were divided into 2 groups, group 1 was treated with S - 1 40mg/m^2 orally twice daily on d1-14, repeated every 3 weeks, group 2 was treated with S - 1 as group 1, and combined with docetaxel 75mg/m^2 intra- venous infusion on d1 , repeated every 3 weeks. The median treatment period of treatment was 3 cycles. Results ： In group 1 the objective response rate（ORR） was 14.3% and clinical benefit rate（CBR） was 35.7%. In group 20RR was 22.7 % , CBR was 72.7 %. There was significantly difference in CBR between 2 groups （ P 〈 0.05 ）. Conclusion ： S - 1 based chemotherapy is effective and tolerable for metastatic lung cancer.